Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$42.12 USD
-0.17 (-0.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $42.09 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Crinetics Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -214.53 | -163.92 | -107.64 | -73.81 | -50.42 |
Depreciation/Amortization & Depletion | -5.17 | 1.02 | 1.34 | 0.72 | -0.34 |
Net Change from Assets/Liabilities | 8.04 | 18.61 | 1.10 | 0.38 | -2.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 45.35 | 29.08 | 16.61 | 10.69 | 6.52 |
Net Cash From Operating Activities | -166.31 | -115.21 | -88.59 | -62.03 | -46.38 |
Property & Equipment | -4.69 | -1.66 | -0.44 | -0.19 | -0.49 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -195.73 | -172.32 | -56.05 | 0.40 | 42.16 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -200.41 | -173.98 | -56.48 | 0.22 | 41.67 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 388.94 | 121.96 | 252.68 | 114.57 | 0.07 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 388.94 | 121.96 | 252.68 | 114.57 | 0.07 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 22.22 | -167.22 | 107.61 | 52.76 | -4.65 |
Cash at Beginning of Period | 33.97 | 201.20 | 93.59 | 40.83 | 45.47 |
Cash at End of Period | 56.20 | 33.97 | 201.20 | 93.59 | 40.83 |
Diluted Net EPS | -3.69 | -3.15 | -2.80 | -2.42 | -2.09 |
Fiscal Year End for Crinetics Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -214.53 | -154.43 | -96.97 | -46.00 |
Depreciation/Amortization & Depletion | NA | -5.17 | -1.85 | -0.88 | -0.25 |
Net Change from Assets/Liabilities | NA | 8.04 | -0.26 | -5.11 | -0.69 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 45.35 | 28.75 | 16.51 | 6.21 |
Net Cash From Operating Activities | NA | -166.31 | -127.79 | -86.45 | -40.72 |
Property & Equipment | NA | -4.69 | -3.75 | -0.25 | -0.02 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -195.73 | -109.35 | 80.44 | 48.77 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -200.41 | -113.11 | 80.19 | 48.76 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 388.94 | 351.02 | 13.14 | 0.48 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 388.94 | 351.02 | 13.14 | 0.48 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 22.22 | 110.12 | 6.88 | 8.52 |
Cash at Beginning of Period | NA | 33.97 | 33.97 | 33.97 | 33.97 |
Cash at End of Period | NA | 56.20 | 144.10 | 40.85 | 42.49 |
Diluted Net EPS | NA | -0.89 | -1.01 | -0.94 | -0.85 |